Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$2,448 Mln
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
Debt to Equity
-2.88
ROE
0 %
ROCE
-50.38 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-1,015.59 Mln
EBITDA
$-1,002.60 Mln
Net Profit
$-1,546.74 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Alvotech (ALVO)
| -40.59 | -17.70 | -38.30 | -44.45 | -7.53 | -- | -- |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
|
|---|---|
|
Alvotech (ALVO)
| 14.80 |
|
S&P Small-Cap 600
| 13.89 |
|
BSE Sensex
| 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is... AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg. Address: 9, Rue de Bitbourg, Luxembourg, Luxembourg, 1273 Read more
COO & Director
Mr. Faysal Kalmoua
COO & Director
Mr. Faysal Kalmoua
Headquarters
Luxembourg
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Alvotech (ALVO) stood at $ 1,221 Mln as on 31-Dec-24
The share price of Alvotech (ALVO) is $7.86 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Alvotech (ALVO) has given a return of -7.53% in the last 3 years.
Alvotech (ALVO) has a market capitalisation of $ 2,448 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Alvotech (ALVO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alvotech (ALVO) and enter the required number of quantities and click on buy to purchase the shares of Alvotech (ALVO).
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg. Address: 9, Rue de Bitbourg, Luxembourg, Luxembourg, 1273
The CEO & director of Mr. Faysal Kalmoua. is Alvotech (ALVO), and CFO & Sr. VP is Mr. Faysal Kalmoua.
There is no promoter pledging in Alvotech (ALVO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Alvotech (ALVO) | Ratios |
|---|---|
|
Return on equity(%)
|
34.47
|
|
Operating margin(%)
|
-12.98
|
|
Net Margin(%)
|
-47.35
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Alvotech (ALVO) was $0 Mln.
$-0.25
(
